BENGALURU (Reuters) – India’s Hetero Labs Ltd said on Wednesday it received local regulatory approval to launch its version of anti-viral drug favipiravir for the treatment of COVID-19.
The drug, priced at 59 rupees (79 cents) per tablet, will be available at drug stores from Wednesday, privately held Hetero said.
(Reporting by Sachin Ravikumar; Editing by Saumyadeb Chakrabarty)
